Filing Details

Accession Number:
0001213900-25-072158
Form Type:
13G Filing
Publication Date:
2025-08-04 20:00:00
Filed By:
Soleus Capital Master Fund, L.P.
Company:
Mural Oncology Plc
Filing Date:
2025-08-05
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Soleus Capital Master Fund, L.P. 0 1,323,877 7.6%
Soleus Capital, LLC 0 1,323,877 7.6%
Soleus Capital Group, LLC 0 1,323,877 7.6%
Soleus Capital Management, L.P. 0 1,323,877 7.6%
Soleus GP, LLC 0 1,323,877 7.6%
Guy Levy 0 1,323,877 7.6%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Soleus Capital Master Fund, L.P. ("Master Fund"). Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC ("SCG") is the sole managing member of Soleus Capital, LLC, Soleus Capital Management, L.P. ("SCM") is the investment manager for Master Fund, and Soleus GP, LLC ("Soleus GP") is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and Soleus GP. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage set forth in row 11 is calculated based upon 17,324,359 ordinary shares of Mural Oncology plc (the "Issuer") outstanding as of July 28, 2025, as reported on the cover of the Issuer's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025, filed with the Securities and Exchange Commission on May 14, 2025 (the "Form 10-Q").


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and Soleus GP. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage set forth in row 11 is calculated based upon 17,324,359 ordinary shares of the Issuer outstanding as of July 28, 2025, as set forth on the cover of the Form 10-Q.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and Soleus GP. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage set forth in row 11 is calculated based upon 17,324,359 ordinary shares of the Issuer outstanding as of July 28, 2025, as set forth on the cover of the Form 10-Q.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and Soleus GP. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage set forth in row 11 is calculated based upon 17,324,359 ordinary shares of the Issuer outstanding as of July 28, 2025, as set forth on the cover of the Form 10-Q.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and Soleus GP. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage set forth in row 11 is calculated based upon 17,324,359 ordinary shares of the Issuer outstanding as of July 28, 2025, as set forth on the cover of the Form 10-Q.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and Soleus GP. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons \s the beneficial owner of such shares for any other purpose. (2) The percentage set forth in row 11 is calculated based upon 17,324,359 ordinary shares of the Issuer outstanding as of July 28, 2025, as set forth on the cover of the Form 10-Q.


SCHEDULE 13G


 
Soleus Capital Master Fund, L.P.
 
Signature:/s/ Guy Levy
Name/Title:Guy Levy/Managing Member
Date:08/05/2025
 
Soleus Capital, LLC
 
Signature:/s/ Guy Levy
Name/Title:Guy Levy/Managing Member
Date:08/05/2025
 
Soleus Capital Group, LLC
 
Signature:/s/ Guy Levy
Name/Title:Guy Levy/Managing Member
Date:08/05/2025
 
Soleus Capital Management, L.P.
 
Signature:/s/ Guy Levy
Name/Title:Guy Levy/Managing Member
Date:08/05/2025
 
Soleus GP, LLC
 
Signature:/s/ Guy Levy
Name/Title:Guy Levy/Managing Member
Date:08/05/2025
 
Guy Levy
 
Signature:/s/ Guy Levy
Name/Title:Guy Levy/Individual
Date:08/05/2025

Comments accompanying signature:  Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)